Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HYdILIC: Hydroxychloroquine vs Diltiazem-Niclosamide in COVID-19
NCT04372082Phase 3Withdrawn
- Sponsor
- CHU de Lille
- Start
- May 2020
- Primary completion
- May 2023
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of hydroxychloroquine, diltiazem, niclosamide in coronavirus disease 2019 (COVID-19), sponsored by CHU de Lille. Planned start May 2020; status: withdrawn.
02
Drugs
hydroxychloroquinediltiazemniclosamide
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04372082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04372082.